TRASTUZUMAB-PKRB | B761091 | CELLTRION INC
Regulatory Exclusivities
| Type | Expiry | Status | Source |
|---|---|---|---|
| 12-Year BPCIA | Dec. 14, 2030 | Active | Computed |
Purple Book Patents
No listed patents in Purple Book.
Estimated Patent LOE
Based on latest discovered patent 12331134(composition) · relevance 88/100
Estimate based on AI-discovered patents. No patents are officially listed in the Purple Book for this product.
Approved Biosimilars
Top 50 of 224 AI-discovered patents by relevance.
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Genentech, Inc. et al v. Celltrion, Inc. et al 40 patentstrastuzumab (anti-HER2 antibody) | D. Del. | 2018-01-12 | Terminated 2018-12-27 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
No patent or exclusivity listings for this strength.